Through bench to bedside translation, we discovered that the PI3K and AR pathways regulate one another in a reciprocal and inhibitory fashion through feedback, explaining the limited efficacy of PI3K pathway inhibitors as monotherapy in clinical trials of patients with metastatic prostate cancer. Based on our work, the first clinical trial of combined PI3K and AR pathway inhibition was recently reported demonstrating a significant benefit for combination therapy in patients with tumors harboring loss of PTEN. Our proposal aims to take these exciting finding back to the pre-clinical space to 1) define biomarkers of intrinsic sensitivity and resistance to inform appropriate patient selection for combination therapy; 2) define the mechanisms of acquired resistance; 3) devise therapeutic strategies to overcome resistance; 4) optimize AR pathway targeting in the setting of PI3K pathway inhibition to maximize tumor response and 5) explore the therapeutic role of FGFR in a novel subset of AR negative prostate cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
4U54CA224079-02
Application #
9985239
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2022-08-31
Budget Start
2017-09-30
Budget End
2019-08-31
Support Year
2
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404
Yan, Yuqian; An, Jian; Yang, Yinhui et al. (2018) Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Mol Med 10:
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Shukla, Shipra; Cyrta, Joanna; Murphy, Devan A et al. (2017) Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell 32:792-806.e7
Bluemn, Eric G; Coleman, Ilsa M; Lucas, Jared M et al. (2017) Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell 32:474-489.e6
Zhang, Pingzhao; Wang, Dejie; Zhao, Yu et al. (2017) Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med 23:1055-1062